Q32 Bio Inc. (QTTB) intrinsic value & 10-year financials
Q32 Bio Inc. (QTTB) has a Graham intrinsic value of $80.38 per share. At $7.52 on Oct 17, 2026, the stock trades 91% below that value. Over the last 10 fiscal years revenue grew 39.1% a year to $53.7M, with an average return on invested capital of 254.8%.
- Graham intrinsic value
- $80.38
- Share price (Oct 17, 2026)
- $7.52
- Price vs Graham value
- 91% below
- Market cap
- $92.6M
- Revenue (FY2025)
- $53.7M
- Revenue growth (10-yr CAGR)
- 39.1%
- ROIC (10-yr avg)
- 254.8%
- Free cash flow (FY2025)
- —
QTTB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $53.7M | $29.8M | $2.42 | — | 31.5% | -49.7% |
| FY2024 | $0 | -$47.7M | -$6.58 | -$67.8M | — | 495.5% |
| FY2023 | $1.2M | -$113.0M | -$1.95 | -$96.5M | -8774.1% | -95.7% |
| FY2022 | $3.2M | -$5.0M | -$0.09 | -$114.9M | -4154.6% | -103.8% |
| FY2021 | $34.0M | -$95.8M | -$1.73 | -$112.1M | -282.4% | -251.0% |
| FY2020 | $2.7M | -$128.7M | — | -$98.1M | -4821.0% | 1533.4% |
| FY2019 | $1.7M | -$103.9M | — | -$113.2M | -6599.2% | — |
| FY2018 | $5.3M | -$57.2M | — | -$67.5M | -1156.8% | — |
| FY2017 | — | -$30.0M | — | $4.5M | — | — |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Q32 Bio Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Q32 Bio Inc. has historically struggled to out-earn its cost of capital, averaging just -38.6% ROIC.
Q32 Bio Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Q32 Bio Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $80.38 per share.